JP2021526795A5 - - Google Patents

Info

Publication number
JP2021526795A5
JP2021526795A5 JP2020567760A JP2020567760A JP2021526795A5 JP 2021526795 A5 JP2021526795 A5 JP 2021526795A5 JP 2020567760 A JP2020567760 A JP 2020567760A JP 2020567760 A JP2020567760 A JP 2020567760A JP 2021526795 A5 JP2021526795 A5 JP 2021526795A5
Authority
JP
Japan
Prior art keywords
caar
domain
cells
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526795A (ja
JP7561036B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035409 external-priority patent/WO2019236593A1/en
Publication of JP2021526795A publication Critical patent/JP2021526795A/ja
Publication of JP2021526795A5 publication Critical patent/JP2021526795A5/ja
Application granted granted Critical
Publication of JP7561036B2 publication Critical patent/JP7561036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567760A 2018-06-05 2019-06-04 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法 Active JP7561036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680769P 2018-06-05 2018-06-05
US62/680,769 2018-06-05
PCT/US2019/035409 WO2019236593A1 (en) 2018-06-05 2019-06-04 Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells

Publications (3)

Publication Number Publication Date
JP2021526795A JP2021526795A (ja) 2021-10-11
JP2021526795A5 true JP2021526795A5 (enExample) 2022-06-08
JP7561036B2 JP7561036B2 (ja) 2024-10-03

Family

ID=68764025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567760A Active JP7561036B2 (ja) 2018-06-05 2019-06-04 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法

Country Status (9)

Country Link
US (2) US11905321B2 (enExample)
EP (1) EP3801642A4 (enExample)
JP (1) JP7561036B2 (enExample)
KR (1) KR20210018833A (enExample)
CN (1) CN112423793A (enExample)
AU (1) AU2019282634A1 (enExample)
CA (1) CA3101028A1 (enExample)
MX (1) MX421685B (enExample)
WO (1) WO2019236593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245343A1 (en) * 2019-06-05 2020-12-10 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
CN114075568A (zh) * 2020-08-18 2022-02-22 苏州博腾生物制药有限公司 靶向烟碱乙酰胆碱受体自身抗体的组合物和方法
WO2022136503A1 (en) 2020-12-22 2022-06-30 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
JP2024545870A (ja) * 2021-12-15 2024-12-13 シャンハイ シンヴィダ バイオテクノロジー カンパニー リミテッド 血小板減少症を治療するための製品及び方法
EP4587478A1 (en) * 2022-09-14 2025-07-23 The Johns Hopkins University Compositions of chimeric autoantigen-t cell receptor (catcr)-t cells and methods of making and using the same
WO2024124155A1 (en) * 2022-12-08 2024-06-13 The Johns Hopkins University Bispecific autoantigen-immune effector cell engaging antibodies and uses thereof
WO2025072450A1 (en) 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Enhanced adoptive cell therapy
CN119265218A (zh) * 2023-11-24 2025-01-07 福建医科大学附属第二医院 一种MuSK抗体检测方法及相应产品
WO2025199276A1 (en) * 2024-03-20 2025-09-25 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5814478A (en) * 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20050227301A1 (en) * 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2983791A4 (en) * 2013-04-11 2016-11-09 Brigham & Womens Hospital METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK
CN113604491A (zh) * 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells

Similar Documents

Publication Publication Date Title
JP2021526795A5 (enExample)
JP2021522790A5 (enExample)
JP2022533092A5 (enExample)
JP7149304B2 (ja) Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ）
Azuma et al. Requirements for CD28-dependent T cell-mediated cytotoxicity
ES2877129T3 (es) Sistema de señalización de receptor de antígeno quimérico (CAR)
JP6986449B2 (ja) ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞
CA2951885C (en) Use of vista agonists and antagonists to suppress or enhance humoral immunity
KR100454396B1 (ko) 단백질-티로신키나제키메라에의한세포면역성의방향전환
US20210253667A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2019513394A5 (enExample)
UA125207C2 (uk) Комбінована терапія для лікування злоякісної пухлини
PT1897548E (pt) Regulação de células t
CN115175935A (zh) Cal-t构建体及其用途
EP3703709A1 (en) Molecular switch-mediated control of engineered cells
JP2021511826A5 (enExample)
RU2016124280A (ru) Клетка
PT1372696E (pt) Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel
JP2025122064A (ja) 細胞
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114249832B (zh) 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
HU224137B1 (hu) Kiméra-receptorokat kódoló DNS-molekulák, a DNS-molekulákat hordozó vektorok és a DNS-molekulákat expresszáló sejtek
JP2022526194A (ja) Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
JP2025063330A (ja) 対合が改善されたｔ細胞受容体ｔ細胞
JP2026509363A (ja) 癌の治療のための抗ｃｄ２７６および抗ｃｄ９９ロジックゲート型キメラ抗原受容体